Cooperative Agreement R44CA221559

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $619,764 to the University of Wisconsin - Madison to develop new combination immunotherapy strategies for treating triple-negative breast cancer (TNBC). The key objectives are to: 1) increase the tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor (P-aPDL1) by triggering local thrombus formation in TNBC tumors, and 2) modulate the immunosuppressive...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Promilead, LLC to activate the TFEB protein and enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The key objectives are to: Determine how TFEB expression and activation in TNBC cells can favorably modulate tumor-associated macrophages to suppress tumor growth. Prior research has shown that TFEB has tumor suppressive roles in breast...

The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...

This federal Project Grant award, valued at $630,171.00, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The award aims to develop a first-in-class targeted radiopharmaceutical therapy (RPT) for the treatment of triple-negative breast cancer (TNBC), which lacks effective hormonal therapies. The key product being developed is a novel variable new antigen receptor (VNAR) binding domain from a nurse shark that targets the c-Met receptor,...

The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...

This federal Project Grant award in the amount of $159,540.00 was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to the University of North Carolina at Chapel Hill to conduct research aimed at characterizing and overcoming MHC-I-mediated immune evasion in triple-negative breast cancer. The key products and services to be delivered under this 2.5-year award include: 1) Functionally and molecularly characterizing MHC-I-low breast tumors to determine how MHC-I loss...

The University of Texas MD Anderson Cancer Center was awarded a $597,289 Cooperative Agreement from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) on July 9, 2025. The objective of this project is to develop a chimeric RNA-driven neopeptide vaccine for the prevention of breast cancer in individuals with germline BRCA1/2 mutations. The research aims to identify and validate MHC Class I immunogenic peptides generated from chimeric mRNA transcripts that can serve...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,129 to The Johns Hopkins University to conduct research on leveraging a DDX3 inhibitor, RK-33, in combination with immunotherapy to treat triple-negative breast cancer (TNBC). The goal is to alter the tumor's metabolic environment in a way that enhances the effectiveness of immunotherapy, potentially leading to an "abscopal effect" where the treatment induces regression...

This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies" at the University of Texas MD Anderson Cancer Center in Houston, TX. The $505,071 award, made on February 15, 2025, will fund research aimed at identifying new cancer-specific antigens and developing innovative T cell-based immunotherapies...

This $399,300 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of an innovative cancer immunotherapy approach at Tiba Biotech LLC, a biotechnology company based in Cambridge, Massachusetts. Specifically, the grant funds the creation of a targeted delivery system that combines enhanced self-amplifying RNA (esRNA) technology and spleen-targeting nanoparticle delivery materials. This platform is designed to stimulate a...